1433401-48-9

Upstream product

• 61072-56-8 4-chloro-2-fluorobenzaldehyde 
• 926664-60-0 (R)-(+)-2-methyl-propane-2-sulfinic acid (E)-1-(4-chloro-2-fluoro-phenyl)-methylideneamide 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 1433401-71-8 [(R)-1-(4-chloro-2-fluoro-phenyl)-propyl]-carbamic acid tert-butyl ester 
• 1433402-26-6 [(R)-1-(4-chloro-2-fluoro-3-iodo-phenyl)-propyl]-carbamic acid tert-butyl ester 
• 1434723-25-7 3-((R)-1-tert-butoxycarbonyl-amino-propyl)-6-chloro-2-fluoro-benzoic acid butyl ester 
• 1433402-42-6 [(R)-1-(4-chloro-2-fluorophenyl-3-boronic acid)propyl]carbamic acid tert-butyl ester 
• 1433402-34-6 {(R)-1-[4-chloro-2-fluoro-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propyl}-carbamic acid tert-butyl ester 
• 856563-04-7 (R)-1-(4-chloro-2-fluoro-phenyl)-propylamine hydrochloride 

Relevant academic research and scientific papers

SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION

The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2

PHARMACEUTICAL COMPOUNDS

The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is selecte